Get the Stockscreener App
74.95
0.78%
-0.59
After Hours:
74.95
Arrowhead Pharmaceuticals Inc stock is traded at $74.95, with a volume of 1.40M.
It is down -0.78% in the last 24 hours and up +1.39% over the past month.
Arrowhead Pharmaceuticals Inc is a commercial-stage pharmaceutical company. It is focused on the development of medicines for diseases associated with genetic abnormalities or protein overproduction. The company develops potential RNAi therapies designed to inhibit the expression of genes known to trigger diseases. Its portfolio includes potential drugs targeting Cardiometabolic, Neuromuscular, Pulmonary, Liver, and other diseases. The company also develops RNAi products and clinical candidates designed to target different cell types within the body.
See More
Previous Close:
$75.54
Open:
$75.55
24h Volume:
1.40M
Relative Volume:
0.68
Market Cap:
$10.56B
Revenue:
$622.01M
Net Income/Loss:
$-271.86M
P/E Ratio:
-34.89
EPS:
-2.1484
Net Cash Flow:
$-45.87M
1W Performance:
-2.24%
1M Performance:
+1.39%
6M Performance:
+85.29%
1Y Performance:
+387.00%
1-Day Range:
$74.53
$76.51
1-Week Range:
$69.88
$78.49
52-Week Range:
$14.30
$82.26
Arrowhead Pharmaceuticals Inc Stock (ARWR) Company Profile
Name
Arrowhead Pharmaceuticals Inc
Sector
Industry
Phone
626-696-4702
Address
177 E COLORADO BLVD, PASADENA, CA
Compare ARWR vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ARWR
Arrowhead Pharmaceuticals Inc
|
74.95 | 10.64B | 622.01M | -271.86M | -45.87M | -2.1484 |
VRTX
Vertex Pharmaceuticals Inc
|
434.52 | 110.03B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
638.88 | 67.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
806.46 | 50.76B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
297.45 | 40.12B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
151.56 | 32.68B | 742.00K | -1.37B | -1.07B | -7.0731 |
Arrowhead Pharmaceuticals Inc Stock (ARWR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-21-26 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jun-05-24 | Initiated | Goldman | Neutral |
| Dec-04-23 | Initiated | BofA Securities | Buy |
| Sep-19-23 | Initiated | Citigroup | Neutral |
| Jul-21-23 | Initiated | TD Cowen | Outperform |
| May-12-23 | Downgrade | SVB Securities | Outperform → Market Perform |
| Apr-26-23 | Initiated | SMBC Nikko | Outperform |
| Apr-12-23 | Upgrade | SVB Securities | Market Perform → Outperform |
| Mar-21-23 | Initiated | Bernstein | Mkt Perform |
| Sep-09-22 | Initiated | Morgan Stanley | Equal-Weight |
| May-11-22 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Jan-19-22 | Resumed | Goldman | Buy |
| Aug-06-21 | Reiterated | Chardan Capital Markets | Buy |
| Jun-04-21 | Resumed | Robert W. Baird | Neutral |
| Feb-05-21 | Reiterated | H.C. Wainwright | Buy |
| Dec-21-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Dec-16-20 | Initiated | UBS | Buy |
| Nov-19-20 | Initiated | Citigroup | Buy |
| May-13-20 | Initiated | RBC Capital Mkts | Outperform |
| May-08-20 | Upgrade | Oppenheimer | Perform → Outperform |
| Apr-15-20 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Mar-24-20 | Upgrade | SVB Leerink | Underperform → Mkt Perform |
| Mar-17-20 | Initiated | Goldman | Neutral |
| Jan-21-20 | Initiated | SVB Leerink | Underperform |
| Dec-13-19 | Initiated | Oppenheimer | Perform |
| Nov-29-19 | Reiterated | Chardan Capital Markets | Buy |
| Nov-27-19 | Reiterated | B. Riley FBR | Buy |
| Nov-25-19 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Oct-24-19 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Oct-22-19 | Reiterated | Chardan Capital Markets | Buy |
| Oct-03-19 | Initiated | Robert W. Baird | Outperform |
| Sep-07-18 | Upgrade | B. Riley FBR | Neutral → Buy |
| Sep-06-18 | Reiterated | Chardan Capital Markets | Buy |
| Aug-08-18 | Reiterated | Cantor Fitzgerald | Overweight |
| Jul-02-18 | Reiterated | Chardan Capital Markets | Buy |
View All
Arrowhead Pharmaceuticals Inc Stock (ARWR) Latest News
Avoiding Lag: Real-Time Signals in (ARWR) Movement - Stock Traders Daily
ARROWHEAD PHARMACEUTICALS IN (ARWR) Technical Analysis - ChartMill
Arrowhead’s ARO-CFB Kidney Trial Completion: What Investors Should Watch Next - TipRanks
Arrowhead Pharmaceuticals Eyes Q3 SHASTA Data as REDEMPLO Approvals Build Momentum - Yahoo Finance
Arrowhead Pharmaceuticals Inc at RBC Capital Markets Global Healthcare Conference Transcript - GuruFocus
Director Daniel Apel to offer 100,000 ARWR common shares (NASDAQ: ARWR) - Stock Titan
Insider Hongbo Lu notifies sale of 2,970 ARWR shares (NASDAQ: ARWR) - Stock Titan
James Hamilton to sell 10,000 shares (ARWR) after prior 10,000-share sale - Stock Titan
Arrowhead Pharmaceuticals eyes $4B Redemplo opportunity as RNAi pipeline readouts near - MSN
Arrowhead Licenses ARO PNPLA3 To Madrigal To Expand MASH Options - Sahm
Q4 2025 Arrowhead Pharmaceuticals Inc Earnings Call Transcript - GuruFocus
What is Zacks Research's Estimate for ARWR FY2026 Earnings? - MarketBeat
Baader Bank Aktiengesellschaft Purchases Shares of 14,194 Arrowhead Pharmaceuticals, Inc. $ARWR - MarketBeat
Insider Sell: Hongbo Lu Sells Shares of Arrowhead Pharmaceuticals Inc (ARWR) - GuruFocus
Transcript : Arrowhead Pharmaceuticals, Inc. Presents at Bank of America Global Healthcare Conference 2026, May-12-2026 through May-14-2026 - marketscreener.com
Insider Selling: Arrowhead Pharmaceuticals (NASDAQ:ARWR) Director Sells 2,970 Shares of Stock - MarketBeat
Arrowhead director Lu Hongbo sells $228,333 of common stock - Investing.com
Arrowhead (NASDAQ: ARWR) director sells 2,970 shares under Rule 10b5-1 plan - Stock Titan
Arrowhead Pharmaceuticals, Inc.Common Stock (NQ: ARWR - FinancialContent
What is HC Wainwright's Forecast for ARWR Q3 Earnings? - MarketBeat
Arrowhead Pharmaceuticals stock hits 52-week high at $80.5 By Investing.com - Investing.com South Africa
Arrowhead Pharmaceuticals Eyes $4B REDEMPLO Opportunity as RNAi Pipeline Readouts Near - MarketBeat
ARWR Maintained by Bernstein -- Price Target Raised to $46.00 - GuruFocus
Sanford C. Bernstein Boosts Arrowhead Pharmaceuticals (NASDAQ:ARWR) Price Target to $46.00 - MarketBeat
Arrowhead Pharmaceuticals stock hits 52-week high at $80.5 - Investing.com
HC Wainwright Issues Optimistic Outlook for ARWR Earnings - MarketBeat
ARWR Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Assessing Arrowhead Pharmaceuticals (ARWR) Valuation After Its Recent Share Price Momentum - Yahoo Finance
[144] ARROWHEAD PHARMACEUTICALS, INC. SEC Filing - Stock Titan
Arrowhead Pharmaceuticals: A True Inflection Point Has Arrived (NASDAQ:ARWR) - Seeking Alpha
Goldman Sachs Maintains Arrowhead Pharmaceuticals (ARWR) Neutral Recommendation - MSN
Arrowhead Pharmaceuticals Jumps 7.9% After RBC Capital Maintains Outperform - AlphaStreet
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Sets New 1-Year High on Analyst Upgrade - MarketBeat
Discipline and Rules-Based Execution in ARWR Response - Stock Traders Daily
Has Arrowhead Pharmaceuticals (ARWR) Run Too Far After Its 488% One Year Surge - Sahm
Arrowhead Pharmaceuticals (ARWR) Q1 Profit Supports Bullish Narrative Despite High 54x P/E - Sahm
ViaSat, Arrowhead Pharmaceuticals, and SiTime Lead Stocks with High Returns - Markets Mojo
Arrowhead anticipates SHASTA-3/4 topline in Q3 while planning an SHTG sNDA before end of 2026 - MSN
Arrowhead Pharmaceuticals’ Earnings Call: Launch, Losses, Bets - TipRanks
ARWR Maintained by RBC Capital -- Price Target Raised to $87.00 - GuruFocus
Madrigal outlays $1bn for Arrowhead’s siRNA MASH asset - MSN
Piper Sandler Maintains Arrowhead Pharmaceuticals(ARWR.US) With Buy Rating, Maintains Target Price $110 - Moomoo
RBC Capital Maintains Arrowhead Pharmaceuticals(ARWR.US) With Buy Rating, Raises Target Price to $87 - Moomoo
RBC Capital Adjusts Arrowhead Pharmaceuticals Price Target to $87 From $80, Maintains Outperform Speculative Risk Rating - marketscreener.com
Chardan Capital Maintains Arrowhead Pharmaceuticals(ARWR.US) With Buy Rating, Raises Target Price to $90 - Moomoo
Arrowhead Pharmaceuticals Reports Fiscal 2026 Second Quarter Results - BioSpace
Arrowhead Pharma earnings up next: First Redemplo sales in focus - Investing.com
Arrowhead Pharmaceuticals (ARWR) Reports Strong Progress and Fut - GuruFocus
EDGAR Filing Documents for 0001628280-24-003492 - SEC.gov
ViaSat, Arrowhead Pharmaceuticals, and Coherent Corp. Lead High-Return Stocks - Markets Mojo
Is Arrowhead Pharmaceuticals on the Cusp of a Major Breakout - Kavout
Arrowhead Pharmaceuticals Inc Stock (ARWR) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.98%
1.33%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):